
Press Release

September 1, 2023

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Announces Change of European Consolidated Subsidiary's Trade Name

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that, on August 31 (local time), it made a decision to change the trade name of its European consolidated subsidiary as below.

1. Details of trade name change

“Myovant Sciences GmbH”, the name of the remaining company after the reorganization of European group companies, will change to “Sumitomo Pharma Switzerland GmbH.”

2. Reasons for trade name change

On August 31, 2023, Sumitomo Pharma made a decision to reorganize multiple European group companies in Switzerland, with “Myovant Sciences GmbH” as the remaining company. It was decided to change the trade name of the integrated company because, holding the intellectual property for such mainstay products as ORGOVYX[®], MYFEMBREE[®], and GEMTESA[®] and assuming the role of product supplier (supply chain function), it will occupy an important position within the Sumitomo Pharma group.

Since the reorganization is among consolidated subsidiaries (second- and third-generation subsidiaries) of the Company, the impact on Sumitomo Pharma's consolidated financial results will be minimal.

3. Date of trade name change

Mid-September 2023 (planned)

4. Overview of respective subsidiary

Company Name	Myovant Sciences GmbH
Head Office	Basel, Switzerland
Representative	Laura Genatossio, General Manager
Description of Business	R&D, manufacturing and sales of pharmaceuticals
Capital	US\$20 (in thousand)
Date of Establishment	August, 2016
Major Shareholder and Shareholding Ratio	Myovant Holdings Ltd., (100% second-generation subsidiary of Sumitomo Pharma Co., Ltd.) 100%

Contact:
Corporate Communications
Sumitomo Pharma Co., Ltd.
E-mail: prir@sumitomo-pharma.co.jp